Change Font Size: A A A A

Bullet Riomet patient profile
Bullet Titrate new patients with Riomet
Bullet Is Riomet right for your patient?
Bullet Order Riomet Samples

Riomet makes Titration possible on new patients

GI symptoms are common in new patients who start on Metformin

GI symptoms can be minimized by Riomet by starting your patients at a lower starting dose and gradually increasing the dosage. Also divided dose can be given with meals

Most Common Adverse Reactions*
Incidence (%)
Adverse Reaction
Metformin
Monotherapy
(n=141)
Placebo
(n=145)
Diarrhea
53.2
11.7
Nausea/Vomiting
25.5
8.3
Flatulence
12.1
5.5
Asthenia
9.2
5.5
Indigestion
7.1
4.1
Abdominal Discomfort
6.4
4.8
Headache
5.7
4.8





Riomet offers more flexible titration option over tablets.

  • 500 mg/ 5 ml liquid enables titration at various dosage levels
  • No cutting or breaking tablets – simple titration cup eliminates guesswork
  • Riomet can be started at low dose, with gradual dose escalation, both to reduce the gastrointestinal side effects and to permit identification of the minimum dose required for adequate glycemic control for the patients

There is no fixed dosage regimen for the management of hyperglycemia in patients with type-2 diabetes with metformin or any other pharmacologic agent. Dosage must be individualized on the basis of both effectiveness and tolerance.

 

Important Safety Information about RIOMET®

RIOMET as monotherapy, is indicated, as an adjunct to diet and exercise, to improve glycemic control in patients 10 years of age and older with type 2 diabetes. RIOMET may be used concomitantly with a sulfonylurea or insulin to improve glycemic control in adults (17 years of age and older).

RIOMET is contraindicated in patients with renal disease or dysfunction, acute or chronic metabolic acidosis, including diabetic ketoacidosis or known hypersensitivity to Metformin hydrochloride.

RIOMET treatment should not be initiated in patients >= 80 years of age unless measurement of creatinine clearance demonstrates that renal function is not reduced, as these patients are more susceptible to developing lactic acidosis. In addition, RIOMET should be promptly withheld in the presence of any condition associated with hypoxemia, dehydration, or sepsis.

Temporarily discontinue in patients receiving intravascular iodinated contrast materials for radiologic studies. Diarrhea, nausea, vomiting, abdominal bloating, anorexia, or flatulence may occur, especially during initiation of therapy.

Not recommended for pediatric patients (under 10 years of age) or pregnant women.

Hypoglycemia does not occur in patients receiving RIOMET alone under usual circumstances of use. Hypoglycemia could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with other glucose-lowering agents (such as sulfonylureas and insulin) or ethanol.

Please see full Prescribing Information, including boxed WARNING regarding lactic acidosis

Please consult with your healthcare professional to see if RIOMET is right for you. The content of this Web site is not a substitute for professional medical advice and should not be interpreted as treatment recommendations or relied on for medical diagnosis or treatment.

   
 

Copyright 2004-2005 © - Ranbaxy Laboratories, Inc.   | Privacy Policy | Sitemap | This site is intended for use by U.S. residents only